BioNexus Gene Lab Corp Files Definitive Proxy Statement

Ticker: BGLC · Form: DEF 14A · Filed: Feb 27, 2025 · CIK: 1737523

Bionexus Gene Lab CORP DEF 14A Filing Summary
FieldDetail
CompanyBionexus Gene Lab CORP (BGLC)
Form TypeDEF 14A
Filed DateFeb 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, sec-filing

TL;DR

BioNexus Gene Lab Corp filed its DEF 14A proxy statement on 2/27/25. Shareholders get voting info.

AI Summary

BioNexus Gene Lab Corp. filed a Definitive Proxy Statement (DEF 14A) on February 27, 2025, for the fiscal year ending December 31, 2024. The filing, with SEC file number 001-41750, details the company's proxy information and is related to its operations as a medical laboratory. The company is incorporated in Wyoming and its principal executive offices are located in Kuala Lumpur.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance and upcoming shareholder meetings, impacting their voting decisions.

Risk Assessment

Risk Level: low — This is a routine filing of a proxy statement, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.

When was this DEF 14A filed by BioNexus Gene Lab Corp?

BioNexus Gene Lab Corp filed this DEF 14A on February 27, 2025.

What is the SEC file number for BioNexus Gene Lab Corp?

The SEC file number for BioNexus Gene Lab Corp is 001-41750.

Where are BioNexus Gene Lab Corp's principal executive offices located?

BioNexus Gene Lab Corp's principal executive offices are located in Kuala Lumpur.

What is the SIC code for BioNexus Gene Lab Corp?

The Standard Industrial Classification (SIC) code for BioNexus Gene Lab Corp is 8071, which corresponds to Services-Medical Laboratories.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on February 27, 2025 regarding BioNexus Gene Lab Corp (BGLC).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing